Twenty‐year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors
Yao Xu,Fanqi Shi,Yanting Zhang,Mengfan Yin,Xiuxin Han,Jinyan Feng,Guowen Wang
DOI: https://doi.org/10.1002/ijc.34694
2023-08-21
International Journal of Cancer
Abstract:What's new? Malignant bone tumors are extraordinarily diverse in clinical presentation, with patients often having nonspecific symptoms that delay diagnosis. Moreover, such tumors are exceedingly rare. In this report, to better understand the epidemiology of malignant bone tumors in China, the authors investigated incidence and mortality rates using information from the Surveillance, Epidemiology and End Results database. Analyses show that from 2000 to 2019, malignant bone tumor prevalence increased in China. The most commonly occurring bone cancer was osteosarcoma, which also had the greatest increase in incidence rate. Mortality and survival differed across subgroups, being influenced by various factors, including age and tumor type. Malignant bone tumors are a group of rare malignant tumors and our study aimed to update the recent epidemiologic estimates based on the Surveillance, Epidemiology and End Results database. Patients diagnosed with malignant bone tumors from 2000 to 2019 were included and their characteristics were retrospectively described. The limited‐duration prevalence, annual age‐adjusted incidence and mortality were calculated, and the annual percentage changes were analyzed to quantify the rate change. Finally, observed survival and relative survival rate were illustrated. Subgroup analysis across tumor type, age, gender, tumor Grade, primary tumor site and stage was also performed. As for results, a total of 11 655 eligible patients with malignant bone tumor were selected. Osteosarcoma was the most common tumor type, followed by chondrosarcoma, Ewing sarcoma and chordoma. The estimated limited‐duration prevalence of malignant bone tumors increased from 2000 (0.00069%) to 2018 (0.00749%). Steady age‐adjusted incidence was observed in all patients during the study period while the highest rate occurred in osteosarcoma. Mortality rates differed in subgroups while elder patients (older than 64 years) presented the highest mortality rate compared to other age groups. In all bone tumors, the 10‐year observed survival and relative survival rates were 58.0% and 61.9%, respectively. Chondrosarcoma patients had the best survival outcome, followed by osteosarcoma, Ewing sarcoma, chordoma and other bone tumors. In conclusion, different epidemiologic performance in incidence and mortality was observed across tumor type as well as other demographic and clinicopathological variables, which provide potential suggestion for further adjustment of medical resource.
oncology